NEW YORK (GenomeWeb) — NovellusDx said today that it has signed a deal with Primetech for the distribution of its functional annotation for cancer treatment (FACT) assay in Japan.
The next-generation sequencing-based FACT assay is designed to test the functional effects of variants of unknown significance in reponse to various cancer treatments to predict clinical results.